You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

DIFLUNISAL - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


Summary for DIFLUNISAL
Drug Prices for DIFLUNISAL

See drug prices for DIFLUNISAL

Drug Sales Revenue Trends for DIFLUNISAL

See drug sales revenues for DIFLUNISAL

Recent Clinical Trials for DIFLUNISAL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Bristol-Myers SquibbPhase 1
Fundação de Amparo à Pesquisa do Estado de São PauloPhase 4
Federal University of São PauloPhase 4

See all DIFLUNISAL clinical trials

Pharmacology for DIFLUNISAL
Medical Subject Heading (MeSH) Categories for DIFLUNISAL
Anatomical Therapeutic Chemical (ATC) Classes for DIFLUNISAL

US Patents and Regulatory Information for DIFLUNISAL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck DOLOBID diflunisal TABLET;ORAL 018445-002 Apr 19, 1982 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Merck DOLOBID diflunisal TABLET;ORAL 018445-001 Apr 19, 1982 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Heritage Pharma DIFLUNISAL diflunisal TABLET;ORAL 202845-002 Aug 16, 2024 RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Zydus Pharms DIFLUNISAL diflunisal TABLET;ORAL 203547-001 Jun 16, 2017 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Heritage Pharma DIFLUNISAL diflunisal TABLET;ORAL 202845-003 Aug 16, 2024 RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Ani Pharms DIFLUNISAL diflunisal TABLET;ORAL 074604-001 Jun 10, 1996 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DIFLUNISAL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck DOLOBID diflunisal TABLET;ORAL 018445-001 Apr 19, 1982 ⤷  Subscribe ⤷  Subscribe
Merck DOLOBID diflunisal TABLET;ORAL 018445-002 Apr 19, 1982 ⤷  Subscribe ⤷  Subscribe
Merck DOLOBID diflunisal TABLET;ORAL 018445-002 Apr 19, 1982 ⤷  Subscribe ⤷  Subscribe
Merck DOLOBID diflunisal TABLET;ORAL 018445-001 Apr 19, 1982 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

DIFLUNISAL Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Diflunisal

Introduction

Diflunisal, a nonsteroidal anti-inflammatory drug (NSAID), is widely used for treating mild to moderate pain, inflammation, osteoarthritis, and rheumatoid arthritis. Here, we delve into the market dynamics and financial trajectory of diflunisal, exploring its current market status, growth prospects, and the factors influencing its demand.

Market Overview

Diflunisal is a salicylate derivative with pharmacologic actions similar to other NSAIDs. It is known for its analgesic, anti-inflammatory, and antipyretic properties, making it a popular choice for managing pain and inflammation associated with various conditions[1].

Current Market Size and Growth

The global market for diflunisal, although not as large as some other NSAIDs, is significant due to its specific use cases. The U.S. market for diflunisal drugs is expected to grow from its current value, although the exact growth rate and market size projections are not explicitly stated in recent reports. However, it is part of a broader NSAID market that continues to see steady demand due to the prevalence of conditions like osteoarthritis and rheumatoid arthritis[4].

Market Drivers

Several factors drive the demand for diflunisal:

Increasing Prevalence of Arthritis

The rising prevalence of osteoarthritis and rheumatoid arthritis, particularly among the aging population, contributes significantly to the demand for NSAIDs like diflunisal. As the global population ages, the need for effective pain management and anti-inflammatory treatments is expected to increase[1].

Clinical Efficacy

Diflunisal's efficacy in reducing pain and inflammation, coupled with its relatively low risk of habituation, tolerance, and addiction, makes it a preferred option for many healthcare providers. Its mechanism of action, involving the inhibition of prostaglandin synthesis, is effective in managing symptoms associated with arthritis and other inflammatory conditions[1].

Generic Availability

The availability of generic versions of diflunisal has made the drug more accessible and affordable for a wider population. Generic prescription products are priced lower than brand-name versions, which helps in increasing market penetration and overall demand[1].

Market Restraints

Despite the positive drivers, there are several challenges that could impact the market trajectory of diflunisal:

Competition from Other NSAIDs

The NSAID market is highly competitive, with numerous other drugs available, such as ibuprofen, naproxen, and celecoxib. This competition can limit the market share of diflunisal, especially if other drugs offer similar or better efficacy profiles[1].

Side Effects and Safety Concerns

Like other NSAIDs, diflunisal can have side effects such as gastrointestinal issues, renal impairment, and cardiovascular risks. These safety concerns can lead to reduced prescriptions and a shift towards alternative treatments with better safety profiles[1].

Financial Trajectory

The financial performance of diflunisal is influenced by several factors:

Pricing

The pricing of diflunisal varies depending on the region and the form of the drug. For example, in the U.S., the cost of diflunisal tablets can range from $1.46 to $1.74 per tablet, making it relatively affordable compared to some other prescription medications[1].

Market Size Projections

While specific projections for the diflunisal market are not detailed, the broader NSAID market is expected to grow steadily. The generic nature of diflunisal and its established use cases suggest that it will continue to be a viable option in the market, contributing to its financial stability and growth[4].

Distribution Channels

The distribution of diflunisal is primarily through pharmacies, both retail and hospital-based. The availability of diflunisal in various forms, including tablets and capsules, and its inclusion in many healthcare systems, ensures a robust distribution network[1].

Key Players

Several pharmaceutical companies are involved in the production and distribution of diflunisal. These include Merck Frosst Canada & Co., Aa Pharma Inc, and Pro Doc Limitee, among others. The presence of multiple manufacturers helps in maintaining a competitive pricing structure and ensuring widespread availability[1].

Conclusion

Diflunisal remains a significant player in the NSAID market due to its efficacy in managing pain and inflammation. While it faces competition from other NSAIDs and has associated safety concerns, its generic availability and established use cases ensure a stable market presence.

Key Takeaways

  • Market Demand: Driven by the increasing prevalence of arthritis and the drug's clinical efficacy.
  • Competition: Faces competition from other NSAIDs, which can impact market share.
  • Safety Concerns: Associated with side effects common to NSAIDs, such as gastrointestinal issues and cardiovascular risks.
  • Financial Stability: Supported by its generic availability and affordable pricing.
  • Distribution: Widely available through various pharmacies and healthcare systems.

FAQs

What is diflunisal used for?

Diflunisal is used to treat mild to moderate pain, inflammation, osteoarthritis, and rheumatoid arthritis.

How does diflunisal work?

Diflunisal works by inhibiting prostaglandin synthesis via the arachidonic acid pathway, which helps in reducing pain and inflammation.

Is diflunisal addictive?

No, diflunisal is a non-narcotic analgesic and does not cause habituation, tolerance, or addiction.

What are the common side effects of diflunisal?

Common side effects include gastrointestinal issues, renal impairment, and cardiovascular risks.

Is diflunisal available in generic form?

Yes, diflunisal is available in generic form, which makes it more affordable and accessible.

Sources

  1. DrugBank Online - Diflunisal: Uses, Interactions, Mechanism of Action
  2. Coherent Market Insights - U.S. Transthyretin Amyloidosis Treatment Market Size and Trends
  3. Market Research Intellect - Oncolytic Virus Drug Treatment Market Size, Scope And Forecast
  4. Market Research Reports - Global Diflunisal Drugs Market Growth 2024-2030

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.